Heron Therapeutics, Inc. (NASDAQ:HRTX)‘s stock had its “buy” rating reiterated by research analysts at Noble Financial in a report issued on Thursday.

Several other research firms have also weighed in on HRTX. Cantor Fitzgerald reissued an “overweight” rating on shares of Heron Therapeutics in a research report on Monday, June 26th. Zacks Investment Research raised Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, July 12th. Cowen and Company reissued a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research report on Friday, May 26th. ValuEngine raised Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Aegis reissued a “buy” rating and issued a $33.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. Heron Therapeutics has a consensus rating of “Buy” and a consensus target price of $31.00.

Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 15.60 on Thursday. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $22.01. The company has a 50-day moving average price of $15.36 and a 200-day moving average price of $14.55.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. On average, analysts expect that Heron Therapeutics will post ($3.74) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Heron Therapeutics, Inc. (NASDAQ:HRTX) Rating Reiterated by Noble Financial” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/11/heron-therapeutics-inc-nasdaqhrtx-rating-reiterated-by-noble-financial.html.

Institutional investors have recently added to or reduced their stakes in the stock. Tang Capital Management LLC increased its position in Heron Therapeutics by 39.7% in the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock worth $129,824,000 after buying an additional 2,457,716 shares during the period. FMR LLC increased its position in Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock worth $120,464,000 after buying an additional 2,158,041 shares during the period. Janus Capital Management LLC increased its position in Heron Therapeutics by 20.2% in the first quarter. Janus Capital Management LLC now owns 5,501,755 shares of the biotechnology company’s stock worth $82,524,000 after buying an additional 925,948 shares during the period. Broadfin Capital LLC increased its position in Heron Therapeutics by 26.9% in the first quarter. Broadfin Capital LLC now owns 4,947,403 shares of the biotechnology company’s stock worth $74,211,000 after buying an additional 1,047,816 shares during the period. Finally, Vanguard Group Inc. increased its position in Heron Therapeutics by 40.2% in the first quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock worth $28,127,000 after buying an additional 537,563 shares during the period.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.